Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices

Geiger et al., Vaccines, doi:10.3390/vaccines10101619, Sep 2022
In vitro study showing that aspirin and metabolite salicylic acid inhibit SARS-CoV-2 viral replication in Vero, A549-ACE2, and Huh-7 cells, and in human precision-cut lung slices. Results indicate inhibition of post-entry pathways.
4 preclinical studies support the efficacy of aspirin for COVID-19:
Geiger et al., 27 Sep 2022, peer-reviewed, 11 authors. Contact: jochen.bodem@uni-wuerzburg.de (corresponding author).
In vitro studies are an important part of preclinical research, however results may be very different in vivo.
Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices
Nina Geiger, Eva-Maria König, Heike Oberwinkler, Valeria Roll, Viktoria Diesendorf, Sofie Fähr, Helena Obernolte, Katherina Sewald, Sabine Wronski, Maria Steinke, Jochen Bodem
Vaccines, doi:10.3390/vaccines10101619
Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino-and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.
Funding: Bayer Vital GmbH funded a part of this study. This publication was supported by the Open Access Publication Fund of the University of Wuerzburg. Conflicts of Interest: Bayer Vital GmbH funded a part of this study but had no role in the design of the study; in the collection, analysis or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
References
Avota, Bodem, Chithelen, Mandasari, Beyersdorf et al., The Manifold Roles of Sphingolipids in Viral Infections, Front. Physiol, doi:10.3389/fphys.2021.715527
Chow, Khanna, Kethireddy, Yamane, Levine et al., Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients with Coronavirus Disease, Anesth. Analg, doi:10.1213/ANE.0000000000005292
Di Bella, Luzzati, Principe, Zerbato, Meroni et al., Aspirin and Infection: A Narrative Review, Biomedicines, doi:10.3390/biomedicines10020263
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect. Dis, doi:10.1016/S1473-3099(20)30120-1
Geiger, Kersting, Schlegel, Stelz, Fahr et al., The Acid Ceramidase Is a SARS-CoV-2 Host Factor, Cells, doi:10.3390/cells11162532
Glatthaar-Saalmuller, Mair, Saalmuller, Antiviral activity of aspirin against RNA viruses of the respiratory tract-an in vitro study, Influenza Respir. Viruses, doi:10.1111/irv.12421
Goldman, Lye, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 Days in Patients with Severe COVID-19, N. Engl. J. Med, doi:10.1056/NEJMoa2015301
Hoffmann, Mosbauer, Hofmann-Winkler, Kaul, Kleine-Weber et al., Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2, Nature
Jancso, Cserepes, Gasz, Benko, Ferencz et al., Effect of acetylsalicylic acid on nuclear factor-kappaB activation and on late preconditioning against infarction in the myocardium, J. Cardiovasc. Pharm, doi:10.1097/01.fjc.0000175240.64444.68
Khoo, Fitzgerald, Fletcher, Ewings, Jaki et al., Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: A Phase I, open-label, dose-escalating, randomized controlled study, J. Antimicrob. Chemother, doi:10.1093/jac/dkab318
Kumar, Xin, Liang, Ly, Liang, NF-kappaB signaling differentially regulates influenza virus RNA synthesis, J. Virol, doi:10.1128/JVI.00909-08
Liu, Han, Blair, Kenst, Qin et al., SARS-CoV-2 Infects Endothelial Cells In Vivo and In Vitro, Front. Cell. Infect. Microbiol, doi:10.3389/fcimb.2021.701278
Liu, Huang, Li, Zhou, Liang et al., Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19, Medicine, doi:10.1097/MD.0000000000024544
Maisonnasse, Guedj, Contreras, Behillil, Solas et al., Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates, Nature, doi:10.1038/s41586-020-2558-4
Mazur, Wurzer, Ehrhardt, Pleschka, Puthavathana et al., Acetylsalicylic acid (ASA) blocks influenza virus propagation via its NF-kappaB-inhibiting activity, Cell Microbiol, doi:10.1111/j.1462-5822.2007.00902.x
Neuhaus, Danov, Konzok, Obernolte, Dehmel et al., Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices, J. Vis. Exp, doi:10.3791/57042
Nilsson-Payant, Uhl, Grimont, Doane, Cohen et al., The NF-kappaB Transcriptional Footprint Is Essential for SARS-CoV-2 Replication, J. Virol, doi:10.1128/JVI.01257-21
Oskotsky, Maric, Tang, Oskotsky, Wong et al., Mortality Risk Among Patients With COVID-19 Prescribed Selective Serotonin Reuptake Inhibitor Antidepressants, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2021.33090
Perlman, Masters, Coronaviridae: The Viruses and Their Replication, Fields Virology
Schmidt, Lareau, Keshishian, Ganskih, Schneider et al., The SARS-CoV-2 RNA-protein interactome in infected human cells, Nat. Microbiol, doi:10.1038/s41564-020-00846-z
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s41422-020-0282-0
Zimniak, Kirschner, Hilpert, Geiger, Danov et al., The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue, Sci. Rep, doi:10.1038/s41598-021-85049-0
DOI record: { "DOI": "10.3390/vaccines10101619", "ISSN": [ "2076-393X" ], "URL": "http://dx.doi.org/10.3390/vaccines10101619", "abstract": "<jats:p>Aspirin, with its active compound acetylsalicylic acid (ASA), shows antiviral activity against rhino- and influenza viruses at high concentrations. We sought to investigate whether ASA and its metabolite salicylic acid (SA) inhibit SARS-CoV-2 since it might use similar pathways to influenza viruses. The compound-treated cells were infected with SARS-CoV-2. Viral replication was analysed by RTqPCR. The compounds suppressed SARS-CoV-2 replication in cell culture cells and a patient-near replication system using human precision-cut lung slices by two orders of magnitude. While the compounds did not interfere with viral entry, it led to lower viral RNA expression after 24 h, indicating that post-entry pathways were inhibited by the compounds.</jats:p>", "alternative-id": [ "vaccines10101619" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-2974-6290", "affiliation": [], "authenticated-orcid": false, "family": "Geiger", "given": "Nina", "sequence": "first" }, { "affiliation": [], "family": "König", "given": "Eva-Maria", "sequence": "additional" }, { "affiliation": [], "family": "Oberwinkler", "given": "Heike", "sequence": "additional" }, { "affiliation": [], "family": "Roll", "given": "Valeria", "sequence": "additional" }, { "affiliation": [], "family": "Diesendorf", "given": "Viktoria", "sequence": "additional" }, { "affiliation": [], "family": "Fähr", "given": "Sofie", "sequence": "additional" }, { "affiliation": [], "family": "Obernolte", "given": "Helena", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-7804-4527", "affiliation": [], "authenticated-orcid": false, "family": "Sewald", "given": "Katherina", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0002-2332-226X", "affiliation": [], "authenticated-orcid": false, "family": "Wronski", "given": "Sabine", "sequence": "additional" }, { "affiliation": [], "family": "Steinke", "given": "Maria", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-1908-4091", "affiliation": [], "authenticated-orcid": false, "family": "Bodem", "given": "Jochen", "sequence": "additional" } ], "container-title": "Vaccines", "container-title-short": "Vaccines", "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 9, 29 ] ], "date-time": "2022-09-29T05:23:16Z", "timestamp": 1664428996000 }, "deposited": { "date-parts": [ [ 2022, 10, 14 ] ], "date-time": "2022-10-14T08:00:33Z", "timestamp": 1665734433000 }, "funder": [ { "award": [ "-" ], "name": "Bayer Vital GmbH" } ], "indexed": { "date-parts": [ [ 2022, 10, 14 ] ], "date-time": "2022-10-14T08:42:35Z", "timestamp": 1665736955962 }, "is-referenced-by-count": 0, "issue": "10", "issued": { "date-parts": [ [ 2022, 9, 27 ] ] }, "journal-issue": { "issue": "10", "published-online": { "date-parts": [ [ 2022, 10 ] ] } }, "language": "en", "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 9, 27 ] ], "date-time": "2022-09-27T00:00:00Z", "timestamp": 1664236800000 } } ], "link": [ { "URL": "https://www.mdpi.com/2076-393X/10/10/1619/pdf", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1968", "original-title": [], "page": "1619", "prefix": "10.3390", "published": { "date-parts": [ [ 2022, 9, 27 ] ] }, "published-online": { "date-parts": [ [ 2022, 9, 27 ] ] }, "publisher": "MDPI AG", "reference": [ { "DOI": "10.1016/S1473-3099(20)30120-1", "doi-asserted-by": "publisher", "key": "ref1" }, { "DOI": "10.1093/jac/dkab318", "doi-asserted-by": "publisher", "key": "ref2" }, { "DOI": "10.1038/s41422-020-0282-0", "doi-asserted-by": "publisher", "key": "ref3" }, { "DOI": "10.1056/NEJMoa2015301", "doi-asserted-by": "publisher", "key": "ref4" }, { "DOI": "10.1038/s41598-021-85049-0", "doi-asserted-by": "publisher", "key": "ref5" }, { "DOI": "10.1001/jamanetworkopen.2021.33090", "doi-asserted-by": "publisher", "key": "ref6" }, { "DOI": "10.1038/s41586-020-2575-3", "doi-asserted-by": "publisher", "key": "ref7" }, { "DOI": "10.3390/cells11162532", "doi-asserted-by": "publisher", "key": "ref8" }, { "DOI": "10.1111/irv.12421", "doi-asserted-by": "publisher", "key": "ref9" }, { "DOI": "10.3390/biomedicines10020263", "doi-asserted-by": "publisher", "key": "ref10" }, { "DOI": "10.1097/MD.0000000000024544", "doi-asserted-by": "publisher", "key": "ref11" }, { "DOI": "10.1213/ANE.0000000000005292", "doi-asserted-by": "publisher", "key": "ref12" }, { "DOI": "10.3389/fcimb.2021.701278", "doi-asserted-by": "publisher", "key": "ref13" }, { "DOI": "10.3389/fphys.2021.715527", "doi-asserted-by": "publisher", "key": "ref14" }, { "article-title": "Coronaviridae: The Viruses and Their Replication", "author": "Perlman", "first-page": "410", "key": "ref15", "series-title": "Fields Virology", "volume": "Volume 1", "year": "2021" }, { "DOI": "10.1038/s41564-020-00846-z", "doi-asserted-by": "publisher", "key": "ref16" }, { "DOI": "10.3791/57042", "doi-asserted-by": "publisher", "key": "ref17" }, { "DOI": "10.1038/s41586-020-2558-4", "doi-asserted-by": "publisher", "key": "ref18" }, { "DOI": "10.1128/JVI.00909-08", "doi-asserted-by": "publisher", "key": "ref19" }, { "DOI": "10.1097/01.fjc.0000175240.64444.68", "doi-asserted-by": "publisher", "key": "ref20" }, { "DOI": "10.1111/j.1462-5822.2007.00902.x", "doi-asserted-by": "publisher", "key": "ref21" }, { "DOI": "10.1128/JVI.01257-21", "doi-asserted-by": "publisher", "key": "ref22" } ], "reference-count": 22, "references-count": 22, "relation": {}, "resource": { "primary": { "URL": "https://www.mdpi.com/2076-393X/10/10/1619" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology (medical)", "Infectious Diseases", "Drug Discovery", "Pharmacology", "Immunology" ], "subtitle": [], "title": "Acetylsalicylic Acid and Salicylic Acid Inhibit SARS-CoV-2 Replication in Precision-Cut Lung Slices", "type": "journal-article", "volume": "10" }